July 26, 2012 — Angion Biomedica Corp. announced that the first patient was dosed in a Phase II multicenter clinical trial evaluating BB3 for the treatment of heart attack (acute myocardial infarction). The first patient, a 69-year-old man, was treated at Yale-New Haven Hospital in Connecticut. This double-blind, placebo-controlled study is designed to enroll 80 patients following a first heart attack.
BB3 is a proprietary small molecule mimetic of hepatocyte growth factor (HGF). During a heart attack, the blood supply to part of the heart is interrupted, causing the surrounding cardiac tissue to die, impairing cardiac function. Subsequently, the healing process leads to chronically diminished pump function as scar tissue replaces damaged muscle. In preclinical studies, BB3 has the ability to not only protect healthy cells from dying, but also the ability to promote tissue regeneration following a heart attack.
For more information: http://clinicaltrials.gov/ct2/show/NCT01539590?term=BB3&rank=1